Lilly drug shows diabetes, weight reduction

Eli Lilly's experimental obesity drug demonstrated significant reductions in both blood sugar levels and body weight during a late-stage clinical trial. This advancement positions Lilly to further solidify its leading role in the highly competitive GLP-1 drug market. The company aims to expand its portfolio with this next-generation therapy, potentially offering a more effective treatment option for type 2 diabetes and obesity patients.